OM
Opaleye Management Portfolio holdings
AUM
$494M
This Quarter Return
-1.03%
1 Year Return
+68.17%
3 Year Return
+608.37%
5 Year Return
+807.76%
10 Year Return
+24,567.29%
AUM
$438M
AUM Growth
+$438M
(-4.6%)
Cap. Flow
+$11.6M
Cap. Flow
% of AUM
2.65%
Top 10 Holdings %
Top 10 Hldgs %
58.99%
Holding
62
New
9
Increased
15
Reduced
17
Closed
11
Top Buys
| 1 |
Immunome
IMNM
|
$13.3M |
| 2 |
Cytokinetics
CYTK
|
$10.8M |
| 3 |
CRGX
CARGO Therapeutics
CRGX
|
$9.12M |
| 4 |
Arvinas
ARVN
|
$5.99M |
| 5 |
Biodesix
BDSX
|
$5.33M |
Top Sells
| 1 |
Crinetics Pharmaceuticals
CRNX
|
$9.83M |
| 2 |
Ocular Therapeutix
OCUL
|
$9.2M |
| 3 |
Compass Therapeutics
CMPX
|
$6.28M |
| 4 |
Catalyst Pharmaceutical
CPRX
|
$5.64M |
| 5 |
NYXH
Nyxoah
NYXH
|
$4.32M |
Sector Composition
| 1 | Healthcare | 98.24% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Harrow
HROW
$1.44B
| $83.4M | 19.04% | 3,990,000 +69,400 | +2% | +$1.45M |
|
2
TG Therapeutics
TGTX
$4.65B
| $40.6M | 9.27% | 2,280,000 | – | – |
|
|
3
Ocular Therapeutix
OCUL
$2.12B
| $36.3M | 8.29% | 5,307,500 -1,345,638 | -20% | -$9.2M |
|
4
Rhythm Pharmaceuticals
RYTM
$6.85B
| $21.1M | 4.83% | 515,000 | – | – |
|
5
Keros Therapeutics
KROS
$618M
| $16.8M | 3.84% | 367,500 | – | – |
|
|
6
Arvinas
ARVN
$568M
| $14.8M | 3.38% | 555,000 +225,000 | +68% | +$5.99M |
|
|
7
Immunome
IMNM
$828M
| $13.3M | 3.05% | +1,102,500 | New | +$13.3M |
|
|
8
Cytokinetics
CYTK
$4.23B
| $10.8M | 2.46% | +198,500 | New | +$10.8M |
|
9
Codexis
CDXS
$246M
| $10.7M | 2.45% | 3,455,000 +335,000 | +11% | +$1.04M |
|
10
Edgewise Therapeutics
EWTX
$1.51B
| $10.4M | 2.39% | 580,000 -85,000 | -13% | -$1.53M |
|
|
11
Catalyst Pharmaceutical
CPRX
$2.52B
| $9.91M | 2.27% | 640,000 -364,355 | -36% | -$5.64M |
|
|
CRGX
12
DELISTED
CARGO Therapeutics
CRGX
| $9.12M | 2.08% | +555,700 | New | +$9.12M |
|
13
Jasper Therapeutics
JSPR
$45.5M
| $8.9M | 2.03% | 392,000 -43,573 | -10% | -$989K |
|
14
Nurix Therapeutics
NRIX
$714M
| $8.74M | 2% | 418,928 +151,718 | +57% | +$3.17M |
|
15
Trevi Therapeutics
TRVI
$883M
| $7.88M | 1.8% | 2,645,000 | – | – |
|
16
Eton Pharmaceutcials
ETON
$464M
| $7.88M | 1.8% | 2,395,000 -50,781 | -2% | -$167K |
|
17
Applied Therapeutics
APLT
$71M
| $7.85M | 1.79% | 1,680,000 -90,000 | -5% | -$420K |
|
18
4D Molecular Therapeutics
FDMT
$288M
| $7.26M | 1.66% | 345,750 +1,627 | +0.5% | +$34.2K |
|
19
Iovance Biotherapeutics
IOVA
$807M
| $7.19M | 1.64% | 897,000 | – | – |
|
|
SLRN
20
DELISTED
ACELYRIN
SLRN
| $6.97M | 1.59% | 1,580,000 | – | – |
|
21
UroGen Pharma
URGN
$900M
| $6.91M | 1.58% | 412,000 +142,000 | +53% | +$2.38M |
|
22
Vaxcyte
PCVX
$4B
| $6.42M | 1.47% | 85,000 | – | – |
|
|
23
Biodesix
BDSX
$62.6M
| $6.15M | 1.41% | 4,020,000 +3,485,343 | +652% | +$5.33M |
|
24
NewAmsterdam Pharma
NAMS
$2.71B
| $6.05M | 1.38% | 315,000 -388 | -0.1% | -$7.45K |
|
25
Xoma
XOMA
$392M
| $5.92M | 1.35% | 250,000 | – | – |
|